OPINION STATEMENT: @entity5202 ( @entity5202 ) is an increasingly diagnosed, immune-mediated disease characterized by inflammation of the esophagus in both @entity1 and adult, causing significant morbidity. Adults typically present with @entity1282 and a history of food impaction. Diagnosis should be considered in @entity1 with histological evidence of @entity1712 (>= 15 eosinophils per high-power field) on esophageal biopsy. More recently, it has been observed that a significant percentage of @entity1 with esophageal @entity1712 respond both clinically and histologically to PPI therapy. This disorder has been named PPI-responsive esophageal @entity1712 (PPI-REE). Recent studies suggest that @entity1 with PPI-REE have similar clinical and endoscopic features of @entity1 with @entity5202 . Specifically, both PPI-REE and @entity5202 @entity1 have a strong disposition to @entity566 compared to @entity1 without @entity1712 . As such, PPI-REE may represent a subset or variant of @entity5202 . Effective treatment of @entity5202 requires a multidisciplinary approach with gastroenterologists, pathologists, allergists, and nutritionists. Treatments include elimination and elemental diets, topical glucocorticoids ( @entity5023 and @entity4184 ), and @entity384 .

Current Approach to the Management of XXXX in Adults.

@entity1 :: ('9606', 'Species') :: ['children', 'patients'] @entity1712 :: ('MESH:D004802', 'Disease') :: ['eosinophilia'] @entity5202 :: ('MESH:D057765', 'Disease') :: ['Eosinophilic esophagitis', 'EoE'] @entity566 :: ('MESH:D006967', 'Disease') :: ['allergy'] @entity384 :: ('MESH:D002311', 'Disease') :: ['endoscopic dilation'] @entity4184 :: ('MESH:D019819', 'Chemical') :: ['budesonide'] @entity1282 :: ('MESH:D003680', 'Disease') :: ['dysphagia'] @entity5023 :: ('MESH:C065382', 'Chemical') :: ['fluticasone']
@entity5202 :: (MESH:D057765,Disease) :: ['Eosinophilic Esophagitis']
